An innovator delivering excellent AI tools for faster and better clinical decisions: Inavya Ventures Ltd.

Inavya Ventures Ltd. is a global AI healthcare startup based in London, dedicated to democratizing access to advanced AI tools to enhance lives. Recognized internationally for its innovative AVATR toolset, co-developed with clinicians and patients across Africa, Asia, Latin America, and Europe, Inavya ensures AVATR is user-friendly and effective in addressing critical healthcare challenges.

A key issue Inavya addresses is non-adherence to treatment plans, a major contributor to poor health outcomes and hospital strain. Factors like confusion, anxiety, mistrust, and poor communication between providers and patients cause non-adherence. Inavya improves health literacy and patient engagement by empowering healthcare professionals to provide clear, relevant information.

Chronic diseases, accounting for 75% of global healthcare costs and projected to reach $47 trillion by 2030, pose a significant financial burden. Addressing non-adherence can reduce these costs and improve patient outcomes. AVATR helps patients create, manage, and share comprehensive digital health profiles, including detailed records, lifestyle data, and real-time metrics, facilitating personalized care.

Utilizing AI technologies like Generative AI (GenAI) and agentic experts, AVATR offers personalized education, reminders, and recommendations to keep patients engaged and informed, enhancing adherence and health outcomes. Inavya’s commitment to data privacy, patient empowerment, and innovation ensures AVATR effectively tackles chronic disease management, transforming healthcare to be more efficient, personalized, and impactful worldwide.

In conversation with Dr Michael Wilkinson, Co-founder and CEO of Inavya Ventures Ltd.

Q. In what ways does AVATR empower patients to take control of their own medical data, and what benefits does this bring to their healthcare management?

We employ a multi-modal approach that utilizes all information formats from within and outside hospitals. Patients prefer receiving information via videos, images, audio, and text. Working with leading teaching hospitals and their outpatients, Dr Peter Sahota of Inavya has developed two enhancements for AVATR AI:

AI Conversational Agents: This interface allows healthcare team members to upload information and outpatients to chat with a RAG-based Generative AI. By providing information through conversational dialogue in the user’s preferred language, this improves confidence in managing healthcare, enhancing patient-physician concordance and treatment adherence.

Agentic AI Multidisciplinary Teams: This toolset allows clinicians, patients, and scientists to assemble synthetic experts for specific tasks. A peer-review panel of synthetic experts provides continuous improvement through machine learning.

Q. Can you discuss some of the key challenges you faced during the development of AVATR and how your team overcame them?

Developing AVATR involved data security, interoperability, user experience, and regulatory compliance challenges. Protecting sensitive medical data was paramount, so the Inavya team implemented advanced encryption and robust authentication mechanisms.  To ensure interoperability, AVATR needed to integrate with various EHR systems. The team developed flexible APIs and used healthcare data standards like HL7 and FHIR for compatibility.  User experience was crucial. Extensive research and testing with patients and healthcare providers led to an intuitive interface. Continuous feedback refined the design and functionality.  Regulatory compliance, particularly with GDPR, was meticulously addressed. Legal advisors worked with developers to embed regulatory requirements into the platform’s architecture, ensuring complete adherence to relevant laws.

Q. Inavya Ventures has achieved significant milestones, including partnerships with the NHS and international collaborations. How have these partnerships contributed to the growth and development of AVATR?

Inavya Ventures co-developed its AVATR technology with world-leading healthcare providers. Collaborations with NHS hospitals like Imperial College and Barts Healthcare allowed real-world testing and adaptation. Feedback from NHS professionals fine-tuned AVATR’s AI features to meet clinical needs.

International partnerships in Italy, Brazil, Peru, and Singapore expanded AVATR’s adaptability and compliance with various medical practices and regulations. These collaborations exposed AVATR to diverse health data and facilitated entry into new markets, supporting global growth.

Q. What advice would you give to other startups aiming to integrate AI and machine learning into healthcare solutions? What key factors should they consider for success?

For AI healthcare startups, focus on:

Data Security and Privacy: Comply with HIPAA and GDPR using encryption and secure access controls.

Real-World Solutions: Engage healthcare professionals and patients to meet their needs.

Data Quality and Diversity: Use high-quality, representative data.

Interdisciplinary Expertise: Combine medical and technical knowledge with regulatory experts.Do you have any new services ready to be launched?

Inavya has developed, tested, and demonstrated a private Retrieval Augmented Generation (RAG) GenAI system for chronic disease management. This system supports multilingual, real-time interaction and translation across multiple formats. AI agents function as on-demand synthetic employees, working independently or collaboratively in multidisciplinary teams. Peer-review rival teams critique each other’s outputs, ensuring robust performance through continuous learning.

Sponsored by Microsoft, Inavya operates on the Microsoft Azure platform, leveraging the open-source LangChain ecosystem for operationalizing LLMs. Language model agents interact with LLMs to intelligently manipulate data, search and retrieve information, and use third-party APIs to perform complex reasoning tasks in response to user queries.

Q. What does the future hold for your company and its customers? Are exciting things on the way?

Inavya has developed a strategic partnership with HealthSum AS, a leading digital health startup based in Oslo. The HealthSum digital health system is underpinned by distributed ledger technology (DLT) and a decentralized hybrid micro-cloud architecture to serve global markets at scale. This novel capability allows for operational functionality without internet connectivity and incorporates AI computing at the edge, deploying our AVATR AI technologies.

Meet the leader behind the success of Inavya Ventures Ltd.

Dr. Michael Wilkinson is the CEO and Co-founder of Inavya. Under his leadership, Inavya was selected as a ‘One World’ and ‘First 100 Playbook’ Company by the UK government. In 2024, it was named a ‘Top-10 Startup to Watch’ (CEO Magazine, USA) and a ‘Top-10 Innovator’ (Innovation in Business, UK).

  Dr. Wilkinson is an appointed AI expert for UK Agencies, the European Commission, and various global governments. He holds a PhD from Warwick University Medical School, where he was a Research Fellow and Overseas Research Scholar. He was a lecturer at the London School of Hygiene and Tropical Medicine, where he founded a Health Informatics Lab and advised WHO. At the National Endowment for Science, Technology, and Arts, he established FutureLab. At the Cabinet Office, he led the ‘Enabling a Digitally United Kingdom’ initiative and wrote the NHS National Innovation Centre business plan, which he subsequently developed.

“Setting a new digital health standard, the synergy between Inavya’s AVATR AI platform and HealthSum’s decentralized technology ensures scalable personalised healthcare across the globe.”